For the year ending 2025-12-31, SLNO made $190,405K in revenue. $20,944K in net income. Net profit margin of 11.00%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Product revenue, net | 190,405 | |||
| Cost of goods sold | 2,700 | |||
| Research and development | 40,627 | |||
| Selling, general and administrative | 132,128 | |||
| Change in fair value of contingent consideration | 5,536 | |||
| Total operating expenses | 180,991 | |||
| Operating income (loss) | 9,414 | |||
| Interest income, net | 16,952 | |||
| Interest expense | 5,476 | |||
| Total other income (expense), net | 11,476 | |||
| Net loss | 20,890 | |||
| Net unrealized gain on marketable securities | 37 | |||
| Foreign currency translation adjustment | 17 | |||
| Total comprehensive income (loss) | 20,944 | |||
| Basic EPS | 0.4 | |||
| Diluted EPS | 0.39 | |||
| Basic Average Shares | 50,817,586 | |||
| Diluted Average Shares | 52,384,886 | |||
SOLENO THERAPEUTICS INC (SLNO)
SOLENO THERAPEUTICS INC (SLNO)